Pharma Journalist

3rd Retinal Imaging Biomarkers & Endpoints Summit
2025-05-27 - 2025-05-29 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The 3rd Retinal Imaging Biomarkers & Endpoints Summit will bring together leading experts spanning medical directors, researchers, clinical, and imaging scientists from more than 30 organizations spearheading ophthalmic development with deep learning systems and sophisticated AI imaging technologies. It’s here they will explore the latest advancements in retinal imaging, biomarkers, and endpoints for ophthalmic drug development.
This highly anticipated meeting will delve into the evolving landscape of retinal diseases, offering in-depth discussions on innovative imaging techniques, biomarker discovery, and the critical role of endpoints in clinical trials. Attendees will have the opportunity to engage with top-tier scientists, researchers, and industry leaders who will be presenting cutting-edge research, techniques, and case studies, providing you with hyper-relevant insights to accelerate your ophthalmic development.
Topics will cover a range of retinal conditions, including dry and wet AMD, GA, GR, and DME, focusing on the identification and validation of biomarkers that are vital for diagnosis, prognosis, and treatment response assessment. This meeting is the perfect bridge for those developing and using novel technologies to ensure the efficacious development of endpoints for regulatory approval.
Attendees will benefit from interactive workshops, panel discussions, and case studies, providing practical insights into the real-world challenges and opportunities in retinal disease research. Plus, with 8+ hours of dedicated networking sessions designed to ensure attendees get to meet everyone in the room, it’s a fantastic opportunity to build valuable connections and strengthen collaboration which will aid in fostering partnerships that will drive the future of retinal imaging and treatment outcomes.
And with sessions being delivered by Alexion, Opus Genetics, Inflammx, Bausch + Lomb, REGENXBIO, and many more you won’t want to miss this!
Whether you’re a researcher, drug developer, clinician or solution provider, the 3rd Retinal Imaging Biomarkers & Endpoints Summit promises to be a pivotal point in the calendar for those involved in the development of therapies for retinal diseases.
Join us to be at the forefront of this rapidly advancing field and contribute to the next wave of innovations in retinal health…
View the event guide for more information: https://ter.li/hcmzr0
Secure your pass: https://ter.li/tq8jmz

2nd Cell & Gene Therapy Pricing & Reimbursement Summit
2025-05-27 - 2025-05-29 | Marriott Washington Capitol Hill, 175 L Street NE, WA, 20002, United States
Current limitations across pricing, coverage, and payment frameworks are lasering out and hindering global access to many approved cell and gene therapies (CGTs). The Cell & Gene Therapy Pricing & Reimbursement Summit is here to change that.
Returning for its 2nd edition, this unique summit will share real-world case studies of success and setback in ensuring patients can access CGTs to spearhead reform in this thorny landscape.
Industry-led discussions will center on innovative payment models being developed and applied, new stop-loss and reinsurance programs, and how leading companies are ensuring coverage and uptake of their commercialized therapies. You’ll also leave with actionable learnings from recent CMS policy changes, including the Access Model, Medicaid Drug Rebate Program Final Rule, and proposed increases to inpatient CAR-T reimbursement rates.
Join leading biopharma, government agencies, commercial payers, academics, and market access-specialist service providers – to align on the current market access strategy and policy challenges hindering widespread adoption of these ground-breaking therapies, enhance your payer coverage and improve patient access.
To know more visit: https://ter.li/0g5eq9

4th Circular & Self-Amplifying RNA Therapeutics Summit
2025-05-28 - 2025-05-29 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
Join the 4th Circular & Self-Amplifying RNA Therapeutics Summit!
Unleashing the Next Generation of RNAs for Widespread Therapeutic Applications
With CSL Seqirus and Arcturus Therapeutics successfully developing the first approved self-amplifying RNA vaccine, the field of next generation RNAs celebrates the potential of circular and self-amplifying RNAs to provide improved stability, durability, longevity and efficacy for treating a wide array of diseases.
This May, the 4th Circular & Self-Amplifying RNA Therapeutics Summit (previously known as ‘Next Generation RNA Therapeutics Summit) is landing back in Boston, as the unique opportunity to unite with leading stakeholders in the next generation RNA field, including the likes of Sail Biomedicines, Merck, Novo Nordisk, Replicate Bioscience and more. This is your one-stop shop to hear the latest approaches and applications of circular and self-amplifying RNA therapeutics and vaccines and gain actionable insights for fast-tracking your RNA programs toward the clinic.
Join 80+ RNA experts navigating through challenges such as RNA design, delivery, purity, and manufacturing to accelerate high-quality and scalable next-generation RNA therapeutics and vaccines towards approval and the patients in need.
To know more visit: https://ter.li/lemzh2

3rd Gene Therapy Potency Assay Summit
2025-05-28 - 2025-05-29 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Accelerating the Route to Commercialization with Robust Potency Assay Development
Following a challenging year in the gene therapy field, the 3rd Gene Therapy Potency Assay Summit returns at a crucial time when drug developers increasingly recognize that a robust potency assay is fundamental to both clinical success and commercial viability. As regulatory expectations continue to evolve, it has never been more important to develop assays that are accurate, reproducible, and aligned with regulatory standards.
While many industry meetings touch on potency in a broad or non-technical manner, this summit stands apart as the only event fully dedicated to the complexities of potency assay development. With an emphasis on deep technical discussions, attendees will gain unparalleled insights into phase-appropriate assay development, methodology advancements, reducing lot-to-lot variability, and meeting evolving regulatory expectations. By bringing together a specialized community of Analytical Development, Quality Control, and Regulatory experts, this meeting offers a unique platform to discuss challenges, share strategies, and explore innovative solutions.
One of the key highlights of this year’s agenda is the session “Navigating Regulatory Requirements for Gene Therapy Potency Assays”, presented by Melody Dai, Vice President, Head of Regulatory Affairs & CMC at Novasenta. This session, taking place at 9:00 AM on Day 1, will provide an in-depth exploration of regulatory strategies for potency assays, covering both early and ongoing regulatory engagement. Attendees will learn how to build effective relationships with regulatory agencies, navigate evolving requirements, and prepare for critical regulatory meetings and submissions. By leveraging insights from experts with hands-on experience in clinical-stage gene therapy products, this session will offer practical guidance that extends beyond theoretical discussions.
With a carefully curated agenda and contributions from industry leaders, the 3rd Gene Therapy Potency Assay Summit provides an essential opportunity to advance potency assay strategies, enhance regulatory preparedness, and accelerate the path to commercialization. Whether you are refining your assay methodologies, tackling regulatory complexities, or preparing for the next phase of development, this event will equip you with the expertise and connections needed to drive success in gene therapy.
Find Out More Now!

2nd Structure-Based Drug Design Summit
2025-06-03 - 2025-06-05 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
With tightening budgets and increasing pressure to de-risk R&D, pharma and biotech are shifting their focus toward smarter, more efficient drug design. Companies are investing more in enabling technologies—from computational modeling and AI-driven predictions to structural biology techniques like Cryo-EM, NMR, and X-ray crystallography—to improve rational drug design and enhance decision-making early in discovery.
While AI-powered structure prediction is transforming the landscape—recognized by the 2024 Nobel Prize for Google DeepMind’s AlphaFold2— its true impact depends on experimental validation. The ability to integrate computational insights with high-resolution structural data is now essential for unlocking complex targets and accelerating drug discovery.
Cryo-EM continues to push the limits of resolution for complex targets and Cryo-ET is emerging as a potential game-changer for biopharma – the future of structure-based drug design is here.
The 2nd Structure-Based Drug Design Summit is the only industry-dedicated meeting bringing together the latest advancements in integrative structural biology and computational tools to accelerate early drug discovery. Across three days of expert-led discussions and case studies, you’ll gain insights into how leading scientists are leveraging Cryo-EM, NMR, X-ray crystallography, and AI to solve high-value targets and drive rational drug design across small molecules, peptides, biologics, and vaccines.
With coverage of design of TPDs, molecular glues, vaccines, antibodies, and mRNA, GPCRs and membrane protein targeting therapeutics plus much more!
The field is evolving—don’t get left behind. Expand your network and join 80+ structural biologists, medicinal chemists, protein engineers, and computational chemists in Boston this June and be part of the next wave of structure-based drug design innovation.

Innovation in Psychosis Therapeutics Summit
2025-06-09 - 2025-06-11 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The Innovation in Psychosis Therapeutics Summit is the premier industry forum dedicated to advancing next-generation approaches for psychosis treatment. As 2025 marks a pivotal year for psychosis drug development—with a surge in clinical advancements and key collaborations gaining momentum—this inaugural event unites the brightest minds in biotech and pharma to overcome critical challenges in drug discovery and development.

Designed specifically for R&D leaders, this summit is uniquely positioned to tackle the biggest hurdles in the field, including translational validity, patient heterogeneity, placebo effect, and trial scalability. By bringing together 60+ key stakeholders from discovery, preclinical, translational, and clinical development, this meeting provides a platform to collaborate, exchange insights, and shape the future of psychosis treatment.
With the growing urgency to address the significant unmet need in psychosis and the limitations of current atypical antipsychotics, the time is now to drive innovation forward. Join the conversation as industry pioneers build on Cobenfy’s breakthrough success and explore cutting-edge strategies to develop more effective, better-tolerated therapeutics across the psychosis spectrum.
Don’t miss this brand-new opportunity to connect with thought leaders, gain critical insights, and be at the forefront of transforming psychosis R&D.
To know more visit: https://ter.li/9yj2vx

7th Annual Allogeneic Cell Therapies Summit
2025-06-10 - 2025-06-12 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
With the autoimmune wave breathing financial life back into the allogeneic space, and a growing number of oncology pipelines entering the clinic, the allogeneic community are eagerly anticipating what lies ahead!
Making now the ideal time to attend the 7th Annual Allogeneic Cell Therapies Summit (June 10-12 | Boston, MA), your flagship forum uniting the top allogeneic developers including Atara Bio, Adicet Bio, Senti Bio, Glycostem and more.
What Will 2025 Offer?

Ground-breaking Clinical Readouts: Dive into the latest results from CAR-T therapies with Atara Bio and Adicet Bio.
Solid Tumor Breakthroughs: Hear from Senti Bio, NKILT Therapeutics, and Synaptimmune on how allogeneic therapies are targeting the tumor microenvironment to unlock entirely new indications.
Manufacturing at Scale: Learn how Tevogen and Cell BioEngines are navigating the complexities of scalable, high-quality manufacturing to make these therapies commercially viable.
Beyond Oncology: Broaden your scope by discovering how Biosyngen and Adicet Bio are leveraging allogeneic platforms to address autoimmune disorders.

As regulatory frameworks evolve to accommodate these revolutionary therapies and investment creeps back into allogeneic development, staying informed is no longer optional. Get involved today to be part of the conversations solving today’s challenges and shaping tomorrow’s breakthroughs.
Find out more: https://ter.li/o21go2

2nd Annual IMPACCT Real World Evidence Summit Europe
2025-06-10 - 2025-06-12 | Steigenberger Airport Hotel, Amsterdam, Stationsplein Zuid-West 951, Schiphol, 1117 CE, Netherlands
This year’s IMPACCT Real World Evidence Europe conference is the only case-study led industry forum providing actionable insights into numerous challenges such as optimizing evidence generation plans in early stages, enhancing collaboration between industry and public research to advance RWE, consolidating cross-functional collaboration to improve effectiveness of RWE studies, and exploring actionable study designs that empower patients to elevate RWE utility…
As regulators and payers increasingly elevate the importance of RWE in submission requirements and with an explosion of datasets opening up in parallel with advancing AI, deep learning, and large language models transforming big data analysis, it has never been more critical to keep up with the matrix of country-specific regulatory nuances and industry case studies in optimizing integrated evidence plans, bullet-proofing data quality, and navigating vendor selection.
The 2nd IMPACCT Real World Evidence Summit Europe is the only industry meeting dedicated to uniting experts in RWE and Evidence Generation to consolidate, innovate and apply RWE across the drug development lifecycle, from external control arms to reimbursement.
With a tight focus on leveraging AI for both efficiency gains and big data analysis, the latest on DARWIN and using RWE to support regulatory decision-making, and creating a robust integrated evidence strategy, join 60+ industry pioneers from AstraZeneca, Pfizer, Novartis, Sanofi and more to collaboratively establish best practice and bridge the evidence gap between clinical research and practice, ensuring resilience and success in a dynamic landscape as a successful business partner.
Join us, our speakers, attendees and sponsors to explore strategies, learn efficient data deployment and automation, learn best practices for sharing real-time data and insights cross-functionally, inform your development processes, address biases and study product life cycle management to bridge the gap from clinical trials to real-world evidence.
With over 50 industry pioneers we have the force to form a comprehensive evidence plan, break free from silos, and bridge the gap between clinical research and practice. Get in the room with Presidents, VPs, Directors, Head, Managers and Lead Scientists all on the same mission as you.
This is your one opportunity to liaise with like-minded, driven and curious individuals about industry innovation.
To know more visit: https://ter.li/e8cs7v

Vendor Management & Outsourcing for Clinical Trials Summit
2025-06-10 - 2025-06-12 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Vendor management processes are crucial for ensuring compliance, quality, and timely delivery at every stage, serving as the backbone of successful clinical trials. Acknowledging the transformative impact, the industry is prioritizing the optimization of these intricate processes, making significant investments to enhance key functions, improve performance, and maintain a competitive edge. Despite this professionals managing ancillary lab vendors and CROs lack a dedicated forum to address their unique challenges, until now…
Introducing the Vendor Management & Outsourcing for Clinical Trials Summit, built with the industry to the needs of vendor management, outsourcing and clinical operations professionals.
To know more visit: https://ter.li/d1jemt

4th World ADC Asia Summit
2025-06-10 - 2025-06-12 | Grand Hyatt Incheon, 208 Yeongjonghaeannam-ro 321beon-gil, Jung-gu, Incheon, South Korea
Linking the East to the West in the ADC World | 在ADC世界连接东西方 | ADC 세계에서 동서 연결하기ADCの世界で東西をつなぐ
In 2025, Asia will continue leading ADC innovation, with growth in dual-payload ADCs, bispecific ADCs, and novel linker-payload technologies. Staying informed through clinical updates, connecting with new companies, and building collaborations will be key to seizing emerging opportunities.
The 4th World ADC Asia Summit (June 10-12, 2025, | Incheon, South Korea), part of the globally recognized World ADC series, serves as the premier platform for showcasing the latest advancements in R&D, clinical validation, and commercialization.
This industry-leading event unites Asia’s top innovators with global expertise to drive ADC success across the region.
What’s New in 2025?
Three dynamic tracks covering discovery, preclinical, clinical, and CMC
Exclusive seminar days on ADC fundamentals & Bispecific ADCs – Whether you’re just starting out or a seasoned expert, the program offers something for professionals at every level
Unparalleled networking with leading experts and organizations
A Global Speaker Lineup
With 20+ new companies joining our esteemed panel from China, Japan, Korea, Taiwan, Singapore, the US, and Europe—featuring industry leaders such as AstraZeneca, AbbVie, HoneyBear Biosciences, Chiome Bioscience, and more—this is a must-attend event for anyone in the ADC field.
Learn more here: https://ter.li/iimxna

10th Annual Microbiome Movement Summit
2025-06-23 - 2025-06-25 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Returning for its 10th anniversary, the Microbiome Movement Summit remains the premier global gathering for microbiome drug developers, uniting experts across discovery, preclinical, translational, regulatory, and commercial sectors to drive innovation in the microbiome space.
Connect with over 140+ experts from diverse fields within microbiome R&D, including representatives from Pulmobiotics, Seres Therapeutics, BiomeBank, and PharmaBiome. Engage in dynamic discussions, forge valuable partnerships, and gain actionable insights that will drive your microbiome research and development forward. This summit is your chance to be at the forefront of microbiome innovation and to collaborate with the brightest minds in the industry.
What’s New for 2025?
– Hear Brand New Insights from Industry Trailblazers: Gain key updates from leaders at Ferring Pharmaceuticals, Siolta Therapeutics, MaaT Pharma, and Corundum Systems Biology as they discuss clinical advancements and commercial strategies shaping the future of microbiome therapeutics.
– 18 New Organizations Taking the Stage: Discover the latest contributions from emerging companies such as Azitra, Kanvas Bio, Alveolus Bio, Microviable Therapeutics, Unilever, Mikrobiomik, Jona, Nestle Health Science, and more, with each presenting their innovative approaches and breakthroughs in microbiome research.
– Unlock the Next Wave of Microbiome-Based Drug Development: Explore groundbreaking synthetic biology innovations, AI-driven strain engineering, and advanced bioinformatics tools that are accelerating the discovery and optimization of microbiome-based therapies.
– Advance Clinical Translation & Regulatory Success: Learn how companies are overcoming challenges in CMC, large-scale manufacturing, and regulatory approval, with insights on recent FDA approvals, IND-enabling studies, and global market access strategies.
Get your copy of the latest brochure here: https://ter.li/cdfr4c

CPHI & PMEC China 2025
2025-06-24 - 2025-06-26 | Shanghai New International Expo Centre, Shanghai, China
CPHI & PMEC China is Asia’s premier pharmaceutical event for sourcing, networking, learning and innovation with over 20 years’ experience of bringing together Chinese and global pharma professionals.

CPHI & PMEC China 2025 will cover more than 230,000 square meters of exhibition area, attract over 90,000 global attendees and 3,500 exhibitors, and hold more than 100 conferences during the exhibition.
CPHI & PMEC China 2025 showcases a wide range of pharmaceutical products and services, including: active pharmaceutical ingredients, Intermediates & fine chemicals, excipients, finished dosage formulation, biopharmaceuticals, natural extracts, CMO & CRO, machinery & equipment, packaging & drug delivery, laboratory equipment, cleanroom & pollution control etc.
Click here to register now.

5th Medical Device Software Development Summit
2025-06-24 - 2025-06-26 | The Royal Sonesta Boston, 40 Edwin H Land Blvd, Cambridge, MA, 02142, United States
The 5th Medical Device Software Development Summit is your must-attend opportunity to gain actionable strategies, real-world case studies, and expert insights to confidently develop, secure, and regulate cutting-edge medical device software – without compromise.
Dedicated to navigating the complexities of US and global regulations, addressing cybersecurity vulnerabilities, and managing legacy device updates, this summit unites 120+ industry leaders – from medical device giants to innovative start-ups – to explore actionable strategies, share best practices, and collaborate on solutions for ensuring the continuous compliance and security of cutting-edge software in a rapidly evolving market.
What Will you Gain:

Stay Ahead of Regulatory Changes: Gain insights from Biogen, Werfen, and Olympus on the latest FDA, EU MDR, and global compliance updates, ensuring your products meet evolving standards.
Secure & Accelerate Your Software: Learn how Medtronic, RETINA-AI, and Abbott are addressing cybersecurity risks, enhancing software validation, and leveraging AI-powered innovation to streamline development processes.
Unlock AI for Safer, Faster Development: Discover how HeartSciences, Kheiron, and Globe Biomedical are utilizing AI to expedite software testing, improve validation, and bolster cybersecurity, leading to safer and more efficient medical device development.

Don’t miss this summit – join us in Boston this June to stay ahead, gain crucial insights, benchmark and fuse knowledge from software, QA, RA and product teams to align innovation in software with evolving processes, cybersecurity, and global regulatory frameworks in new and legacy devices.
View the full Event Guide here: https://ter.li/cziksw

8th International Neoantigen Summit
2025-06-24 - 2025-06-26 | Steigenberger Airport Hotel Amsterdam, Stationsplein Zuid-West 951, 1117 CE Schiphol, Netherlands, 1117 CE, Netherlands
2024 saw a wealth of clinical progression with Nouscom, CureVac, Transgene and other pioneering companies paving the way for neoantigen based vaccines and therapies to become tolerable, durable medicines to effectively treat cancer.
Ready to unite the global neoantigen community, the 8th International Neoantigen Summit 2025 returns to address key challenges in the discovery, translation and clinical development of safe and cost-effective neoantigen therapies and vaccines to attract investors and ultimately improve the health of patients.
Join neoantigen leaders from the likes of AstraZeneca, Geneos Therapeutics, Evaxion Biotech and many more at this end-to-end meeting, focusing on the development of durable, neoantigen cancer vaccines and cell therapies. With the potential to deliver safe, efficacious personalized or off-the-shelf therapeutic options to patients, this is your chance to collaborate and accelerate the translation of neoantigen-based therapies from discovery to clinical success.
To know more visit: https://ter.li/zdfjes

5th Annual Induced Proximity-Based Drug Discovery Summit
2025-06-25 - 2025-06-26 | The Westin San Diego Bayview, 400 W Broadway, San Diego, CA, 92101, United States
Coming to San Diego, CA for the first time, the 5th Induced Proximity-Based Drug Discovery Summit returns as your intimate learning and networking setting to cover the depth and breadth of proximity-based drugs from stabilization, phosphorylation and methylation to novel lysosome-based degradation to finally drug the undruggable.
Enabling leaders in biopharma and academia to identify novel MoAs, leverage advanced technologies to find targets more efficiently, and optimize chemical structures for more effective therapeutic agents for a wide range of disease areas. Alongside key strategic updates on DUBTACs, RIPTACs, tPRIMEs, RiboTACs and more, it provides granular technical and scientific insights to overcome challenges in accessing diverse chemical matter and designing selective, potent small molecules of tomorrow.
Join 70+ experts in drug discovery, medicinal chemistry, chemical biology and structural biology from leading companies such as Genentech, Halda Therapeutics and Stablix and gain access to genuinely innovative research from breakthrough companies and academic labs pioneering the next generation of induced proximity-based drugs beyond the ubiquitin proteasome system
Download the event guide for full details: https://ter.li/blor1c

4th Liquid Biopsy for Precision Oncology East Coast
2025-06-26 - 2025-06-27 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
The 4th Liquid Biopsy for Precision Oncology East Coast Summit returns to Boston with a refreshed agenda, sharpened focus, and a renewed mission: to accelerate access to more sensitive, less invasive testing by addressing the most pressing challenges across the entire patient care continuum.
This year, we’ve updated the Summit’s name and expanded its scope. What began with a focus on early detection and recurrence monitoring has grown to reflect the full breadth of innovation across the liquid biopsy space – from MRD and treatment response to emerging applications in rare diseases, novel analytes, and beyond.
Bringing together leaders in Biomarker Development, Translational Research, Diagnostics, Clinical Development, Pathology, and beyond, this is the go-to East Coast forum for diving deep into the barriers slowing the adoption of liquid biopsy technologies.
Take home actionable insights to ensure you’re maximizing the value of liquid biopsies in your therapeutic development strategies. Shape the future of precision oncology and be part of the conversations that will drive meaningful change for patients worldwide.
What’s more, this event is completely *FREE for drug developers and researchers for the entire 2 day conference, so claim your pass here (it only takes 2 minutes): https://ter.li/mr0yvh
If you need to explore the full event guide in more detail, feel free to download the brochure here: https://ter.li/mxugsc
T&Cs are available on the website.

ESG in Life Sciences Summit West
2025-07-08 - 2025-07-10 | The Clift Royal Sonesta San Francisco, 495 Geary St, San Francisco, CA, 94102, United States
The ESG in Life Sciences Summit West – Mastering ESG Compliance & Strategic Sustainability in Life Sciences in 2025.
As ESG becomes a key differentiator for securing business and investment, life sciences companies are ramping up sustainability efforts – expanding teams, funding new initiatives, and integrating ESG into corporate strategy. Yet, with shifting global reporting requirements, the new administration’s stance on sustainability, and the impact of CSRD on U.S. operations, many companies are struggling to find the golden ticket on how they can future-proof ESG initiatives and ensure accuracy in reporting?
At the same time, mounting pressure from investors, consumers, and employees to accelerate environmental and social initiatives is leaving many searching for the most effective strategies to navigate the evolving ESG landscape.
Following the success of our Boston and European editions, the ESG in Life Sciences Summit West is bringing together senior leaders in ESG, Sustainability, Compliance, Procurement, Supply Chain, and Finance from across the West Coast to:

Decode the impact of evolving U.S. and EU regulations on ESG reporting
Drive sustainable supply chain transformation
Optimize ESG strategies for business growth

Join us in driving the future of Life Sciences sustainability – turning ambition into action, compliance into opportunity, and responsibility into lasting impact for people and the planet! Find out more here: https://ter.li/oggmq8

3rd ADC Toxicity Summit
2025-07-08 - 2025-07-10 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
“Toxicity is the killer of ADCs” and remains the primary challenge limiting ADC success in the clinic. From unpredictable off-target effects to non-translating toxicity profiles and dose limiting toxicities, the industry must address key hurdles in preclinical models, patient selection, ADC design, and cross-disciplinary communication to accelerate the next wave of safer, more effective ADCs.
The 3rd ADC Toxicity Summit is the only industry-led event bringing together toxicology, pharmacology, translational science, and clinical development experts to accelerate bench-to-bedside-to-bench innovation by preventing, predicting, and mitigating toxicities to enhance ADC safety and clinical translation.
To know more visit: https://ter.li/57358v

3rd Obesity & Weight Loss Summit
2025-07-14 - 2025-07-16 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The 3rd Obesity & Weight Loss Summit has been announced and is set to ignite the field. The summit will unite experts to harness novel targets and GLP combination therapies to improve efficacy, tolerability, and longer lasting clinical outcomes.

Join us at this unique, industry-led summit to:

Discover groundbreaking combination therapies and novel targets to minimize and manage side effects to improve patient tolerability with Boehringer Ingelheim and Altimmune
Explore innovative approaches for preserving muscle mass whilst still achieving significant weight loss to prevent sarcopenia with Regeneron and iBio
Investigate cutting-edge advancements in drug delivery technologies, including long-acting formulations and novel administration routes for simpler patient use with Biolexis and Syntis Bio
Learn strategies to drive long-term weight management success by personalizing treatment for more prolonged patient continuation and satisfaction with Prive Bio and Fractyl Therapeutic

Hear from the titans of the pharmaceutical industry – Eli Lilly, Novo Nordisk, AstraZeneca, Altimmune, High Tide Therapeutics, RenBio, and many more – as they share their groundbreaking research and strategies for developing more effective, tolerable, and long-lasting weight management solutions.
Obesity rates are increasing, and the pressure is on for real change. Don’t miss this pivotal opportunity to network with 70+ obesity scientists and drug development experts forge collaborations, and be part of the solution. The future of weight loss treatment is being written now – be there!
For more information, view the full Event Guide here: https://ter.li/rish42

5th Inner Ear Disorders Therapeutics Summit
2025-07-15 - 2025-07-17 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
Building on recent breakthroughs in gene therapy, 2025 is poised for major advancements in cell transplants, gamma secretase inhibitors, anti-inflammatory programs, and more to address the growing unmet need for more transformative hearing loss treatments.

With an aging population and an urgent need to restore a greater spectrum of hearing abilities beyond the scope of current device-based interventions, there has never been a more critical time for the field to unite and drive progress.
Coined by industry as the only meeting of its kind, uniquely positioned to share fresh ideas and assess viable approaches to your most pressing preclinical, translational, and clinical bottlenecks, the 5th Inner Ear Disorders Therapeutics Summit returns as your definitive forum to benchmark learnings from past failures and ignite renewed optimism into the hearing loss therapeutic landscape.
With pioneering insights from Regeneron, Biogen, Acousia, Rinri, Ting Therapeutics, Lineage Cell Therapeutics, Gateway and more, join 50+ of your peers to:

Advance translatable models to recapitulate complex human inner ear pathophysiology
Deepen knowledge of molecular and genetic pathways underlying age-related, noise-induced, and congenital hearing loss to uncover druggable pathways
Evaluate clinical progress in gene therapy for restored hearing and decipher the journey to success in Phase III populations
Overcome translational challenges of bringing advanced therapies, including small molecule and cell-based approaches, to the clinic
Uncover opportunities for drug-device combinations to enable precise drug delivery and enhance the hearing preservation capabilities of cochlear implants
Hear large pharma and investor perspectives on what must be demonstrated to de-risk business opportunities within the hearing disorders space

Join this unparalleled forum of biotech innovators, pharma stakeholders, medical device manufacturers, and leading academics in a collaborative atmosphere to advance otoprotection, hearing restoration, and gene therapy R&D and transform the treatment of hearing loss.
Find out more in our brochure: https://ter.li/22rawz

5th mRNA-Based Therapeutics Summit
2025-07-21 - 2025-07-23 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
The mRNA field is on the cusp of revolutionary change, with cancer vaccines, in vivo cell engineering and gene editing technologies unleashing the next advancements of therapeutic candidates and developmental progress towards clinical and commercial approval.
To shine light on emerging areas and the latest progress, the 5th mRNA-Based Therapeutics Summit returns to Boston as the world’s largest, end-to-end mRNA conference, gathering 350+ global stakeholders, sharing exclusive scientific and strategic insights from the biggest and newest players in the mRNA, Circular RNA & SaRNA fields including Moderna, Pfizer, BioNTech, Grann Pharmaceuticals, Celestial Therapeutics.
Discover the realms of new infectious disease platforms, combating oncological targets and cell therapies across 4 dedicated tracks of content in Discovery, Pre-Clinical Development, Clinical Development and Manufacturing & CMC, as your one-stop-shop scientific content and partnering forum to aid the progress of pipelines in 2025 towards the clinic and ultimately patients in need.
Download the event guide for full details: https://ter.li/esarrv

13th Tumor Models Summit Boston
2025-07-22 - 2025-07-23 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
This July, the 13th Tumor Models Summit Boston returns, uniting 180+ preclinical and translational experts from biopharma and solution providers.
This year’s dual-track program will empower you and your team to implement reproducible, predictive oncology models, and bridge the translational gap in a time- and cost-effective manner.
Expect to gain exclusive insights into:

The latest applications of tumoroids, patient-derived in vivo, ex vivo, in silico and genetically engineered models
Optimized protocols to humanize complex in vitro and mouse models
Applying reverse translation and clinical learnings to better stratify patients, focus treatment regimens, and improve patient outcomes
Practical applications of digital pathology and spatial biology to advance your model selection strategy

Event information and quick links:

Location: Westin Boston Seaport District, Boston, MA
Dates: July 22-23, 2025
Event Guide: https://ter.li/dz9th5
Registration (FREE* for biopharma!): https://ter.li/d6bden

*Subject to terms and conditions, visit the website to learn more: https://ter.li/d6bden

4th Targeted Radiopharmaceuticals Summit US
2025-07-29 - 2025-07-31 | The Hyatt Regency La Jolla, 3777 La Jolla Village Drive, San Diego, CA, 92122, United States
As demand for radiopharmaceuticals rises, the industry is focused on strengthening isotope supply, improving patient access, and accelerating therapeutic development.

Join us at the 4th Targeted Radiopharmaceuticals Summit US in San Diego this July for the premier platform dedicated to radiopharmaceutical therapeutics and theranostics, featuring:

50+ Expert Speakers from leading biotech, pharma, and research institutions, including Ratio Tx, Abdera, Alpha-9
Oncology, Novartis, AstraZeneca, UCLA, UCSF, and more
275+ Industry Attendees driving advancements from bench to bedside
11+ Hours of Networking with top professionals
3 Dedicated Tracks: Discovery & Preclinical, Translational & Clinical, and Clinical & Supply Chain, curated to address key challenges

Offering a tightly focused agenda dedicated to industry-specific topics, this event is designed to advance approvals and commercialization.
Explore critical areas such as isotope supply, clinical development, regulatory clarity, novel molecule design, investment and funding and much more.
Don’t miss this essential event for anyone involved in the radiopharmaceuticals space!
View the exclusive program here.

Operationalize: Expanded Access Programs Summit West
2025-07-29 - 2025-07-31 | The Clift Royal Sonesta, 495 Geary Street, San Francisco, CA, 94102, United States
The Operationalize: Expanded Access Programs Summit West is coming to San Francisco! (July 29-31).
Following the successful Boston and London meetings, the Operationalize Expanded Access Programs Summit West is uniting stakeholders executing Early Access, Expanded Access and Post-Trial Access Programs to share expertise in successfully bridging the gap between innovative clinical research and patients in need.
This Summit is the only West Coast forum connecting Expanded Access teams with industry peers to share case studies in overcoming operational and regulatory challenges to streamline access to life-changing therapies!
Find out more at our website: https://ter.li/9ft05e.
Join 60+ experts, from Eli Lilly, Gilead, Ultragenyx, Daiichi Sankyo and more for three jam-packed days in San Francisco this July. Get exclusive insights, real-world case studies and cutting-edge strategies to supercharge your Expanded Access Programs.

5th Fc-Mediated Function Summit
2025-07-29 - 2025-07-31 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The landscape of Fc-mediated therapies is undergoing a radical transformation, driven by precise Fc-receptor targeting and antibody domain modification to unlock new levels of efficacy and safety for unprecedented therapeutic potential in oncology and autoimmune disease treatment. The 5th Fc-Mediated Function Summit is the essential destination for experts driving innovation in Fc-receptor targeting and antibody domain modification.
This year, we’re evaluating the cutting-edge of Fc biology and engineering, diving deep into the game-changing potential of novel Fc modifications, bispecific formats, and targeted effector functions to revolutionize the treatment of cancer, autoimmune diseases, and beyond. Hear from the titans of the pharmaceutical industry, including AbbVie, Novartis, and UCB as well as innovative biotechs including Seismic Therapeutics, Paradigm Immunotherapies, and many more – as they share their groundbreaking research and strategies for developing more effective, safer, and long-lasting fc-mediated solutions. The therapeutic potential of Fc-mediated functions is surging following last year’s wave in FDA approvals from BeiGene’s Tevimbra to Genetech’s approval of Piasky, and the pressure is on to continue this success and develop best-in-class treatments.
Why Attend?

Navigate the latest insights into Fc receptor interactions and unlock the potential of precisely engineered antibodies for targeted efficacy and enhanced safety profiles
Confront the challenges in therapeutic antibody development head-on by exploring novel Fc engineering strategies and optimizing treatment outcomes across diverse disease indications
Hear from 22+ industry luminaries and thought leaders, including Sally Ward and Richard Blumberg, and a multitude of companies who are pushing the boundaries of antibody engineering and Fc-mediated therapeutics, including Argenx, UCB, and Boehringer Ingelheim

Don’t miss this pivotal opportunity to network with 50+ leading scientists and drug development experts in the field of Fc-Mediated Function, forge crucial collaborations, and be part of the solution. The future of antibody therapeutics is being written now – be a part of it!
Register now.

5th Next Generation Gene Therapy Vectors Summit
2025-07-29 - 2025-07-31 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
The 5th Next Generation Gene Therapy Vectors Summit

Recent announcements from major pharmaceutical companies scaling back their AAV gene therapy pipelines have raised concerns across the field. However, this is not the end. It is an opportunity to reset, refocus, and rise to the challenge. While issues such as liver toxicity, pre-existing antibodies, and high manufacturing costs remain significant, so too does the unmatched potential of AAV vectors. From their ability to cross the blood-brain barrier to delivering single-stranded DNA for single-dose cures, AAV continues to offer enormous therapeutic promise.
The 5th Next Generation Gene Therapy Vectors Summit returns to Boston this September to spotlight the scientists and leaders who are continuing to innovate in vector design. This meeting is designed for those who understand that strategic setbacks can often pave the way for transformative breakthroughs, as we saw in the early development of ADCs.
Over the course of 3 days, the summit will bring together experts in vector engineering, translational science, and clinical development to explore how the field can advance in a more refined and resilient direction. Attendees will hear from thought leaders such as Daniel Cohen (Spark Therapeutics), Eric Kelsic (Dyno Therapeutics), Jorge Santiago-Ortiz (Apertura Gene Therapy), Lolita Petit (Coave Therapeutics), Ralf Schmid (Novartis), and Roxanne Croze (4D Molecular Therapeutics).
The program will explore the latest innovations in capsid engineering, novel strategies to overcome immune responses, scalable systemic delivery technologies, and key clinical insights that can shape future development pipelines.
Whether your focus is vector optimization, CMC, or clinical translation, this summit provides a valuable opportunity to connect with the experts and technologies leading the next phase of gene therapy innovation. Join the community in Boston this July and help shape a safer, smarter, and more successful future for AAV.
Find Out More Here: https://ter.li/8qkdsh

LEAP HR: Life Sciences East
2025-08-05 - 2025-08-07 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Join us this August in Boston, MA for the 9th LEAP HR: Life Sciences East.
Connect with 200+ leadership professionals in biopharma dedicated to attracting, retaining and developing critical talent to deliver their organizations mission. Engage with HR leaders who are also navigating a period of uncertainty amongst: regulation changes, financial uncertainties, supply chain disruptions, and changing workforce dynamics. Leave with a ready-made support network of industry peers committed to building high-performing organizations.
Explore 40+ case studies from leading drug development organizations on shifting to new systems of empowered teams, accelerating the development of both current and future leaders, and optimizing global team dynamics across diverse business layers.
Find out more now: https://ter.li/v3bct4

3rd ADC Linker & Conjugation Summit
2025-08-19 - 2025-08-21 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
As dual-payload and novel MoA payload ADCs continue to reshape the therapeutic landscape, the 3rd ADC Linker & Conjugation Summit returns as the definitive forum for ADC chemists and bioconjugation specialists aiming to overcome persistent challenges in hydrophobicity, aggregation, and linker stability.
This three-day technical deep dive is your chance to:

Discover next-generation conjugation strategies and site-specific technologies
Tackle the unique challenges of dual-payload and novel payload ADCs
Benchmark cutting-edge solutions for improved DAR control and linker stability
Advance ADC reproducibility and performance with chemistries beyond maleimide

Join 80+ industry experts, including ADC chemists, biotech innovators, and service providers, all focused on refining ADC design for enhanced PK profiles and safety.
Explore the brand-new event guide and be part of the community driving the next wave of ADC innovation. https://ter.li/387nz1

9th IPF Summit
2025-08-19 - 2025-08-21 | Hilton Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
This August, the 9th IPF Summit returns as the industry’s must attend summit, providing an essential platform for the entire community to gather and dissect the latest breakthroughs and setbacks, to shape the future of pulmonary fibrosis drug development.
Be one of the first to view the agenda here: https://ter.li/moky9n
A Snapshot of What Awaits You in 2025:

Case Study on the Path to Phase 3 Success: Hear directly from Boehringer Ingelheim’s Susanne Stowasser and Matthew Thomas as they unpack nerandomilast’s journey from discovery through to clinical success
Brand-New From Setbacks to Solutions Seminar Afternoon: Analyze recent Phase 2 and 3 trial failures from with expert insights from Pfizer and former leaders at Galecto and Galapagos
Navigating a Shifting Treatment Landscape: Explore how clinical benchmarks are changing and how new therapies must position themselves, with input from Boehringer Ingelheim, BMS, and Insilico Medicine
Enhancing Preclinical Confidence: Discover what a high-confidence translational package looks like in 2025, featuring case studies from GSK, Boehringer Ingelheim, and others.

If ever there was a time to invest in this community and a conference, it’s now. Join us to gain the full spectrum of insight needed to bring better IPF therapies to patients – faster.
Find all the information needed here: https://ter.li/moky9n

5th Oligonucleotides for CNS Summit
2025-08-27 - 2025-08-29 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
In a year where neurology has overtaken cancer as the number one indication prioritized by oligonucleotide drug developers, now is the time to stay at forefront of ASO and siRNA innovation. Returning to Boston, this August, the 5th Oligonucleotides for CNS Summit unites 100+ biopharma leaders across RNA biology, oligonucleotide chemistry, DMPK, pharmacology, and platform technology, to discover the latest advancements in brain delivery, chemistry, nonclinical safety and more!
Join your peers Alnylam Pharmaceuticals, Denali Therapeutics, Genentech, FDA, Novo Nordisk, Regeneron, Servier, Stoke Therapeutics, Ultragenyx Pharmaceutical and more, to overcome key challenges, build cross-modality relations, unpack the latest clinical data and redefine the landscape of oligonucleotide research.
What to Expect:

Benchmark your chemistry and biology innovations with dual-tracked workshops developed for medicinal chemists and neurobiologists
Hear from 10+ new speakers, including insights from the FDA and companies breaking ground across neuromuscular, neurodegenerative, neurodevelopmental and ultra-rare indications
Explore the next wave of delivery tech, from TfR1 and AOCs to computational CNS PK/PD modeling and novel RNA editing approaches

Capitalize on the recent ‘oligonucleotide boom,’ by attending this meeting!
To know more visit: https://ter.li/uw2usc
